-
Treatments that can slow the disease in some patients have recently become more widely available, but not everyone can benefit.
-
In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.